Cancer in Slovakia

IARC estimates 31,384 new cancer cases and 15,341 cancer deaths in Slovakia in 2024; the commonest new cancers are colorectum, breast and prostate. This page is assembled automatically from OnCo's data: 110 trials with a site there, 1 institution and 1 person, and says what OnCo does not yet hold.

Cancer figures, GLOBOCAN 2024

Compare countries →

New cases

31,384

all cancers

Deaths

15,341

all cancers

Incidence rate

286.1

per 100,000, age-standardised

Mortality rate

121.9

per 100,000, age-standardised

Cumulative risk

27.9%

of a cancer by age 74

Population

5,506,763

IARC, 2024

Most new cases

Site	New cases	Rate	OnCo page
Colorectum	4,402	36.9	Colorectal cancer
Breast	3,803	79.4	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Prostate	3,335	61.8	Prostate cancer
Trachea, bronchus and lung	2,677	22.7	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Bladder	1,354	10.8	Bladder & urothelial cancer
Corpus uteri	1,153	22.3	Endometrial cancer
Kidney	1,101	10.2	Renal cell carcinoma
Pancreas	1,084	8.8	Pancreatic ductal adenocarcinoma
Melanoma of skin	901	9.3	Melanoma
Stomach	888	7.3	Gastric & gastro-oesophageal junction cancer

Most deaths

Site	Deaths	Rate	OnCo page
Colorectum	2,360	17.7	Colorectal cancer
Trachea, bronchus and lung	2,272	18.4	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Breast	1,171	16.6	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Pancreas	1,024	8.1	Pancreatic ductal adenocarcinoma
Prostate	869	14.7	Prostate cancer
Stomach	703	5.5	Gastric & gastro-oesophageal junction cancer
Liver and intrahepatic bile ducts	503	3.9	Hepatocellular carcinoma
Bladder	494	3.4	Bladder & urothelial cancer
Leukaemia	464	3.7	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia
Kidney	455	3.6	Renal cell carcinoma

Incidence: method 3a, national mortality estimates applied to model-based mortality-to-incidence ratios (country-specific registry data).
Mortality: method 1, trends in national rates projected to 2024.
Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “Slovakia”, in Eastern Europe (Europe), Very High HDI, high income.
Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trials with a site here

110 trials in OnCo · 25 recruiting overall

110 trials

Trial			Lead sponsor
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer NCT06890598	Phase 3	Recruiting	Eli Lilly and Company	366	2026-10-07
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) NCT06136650	Phase 3	Recruiting	Merck Sharp & Dohme LLC	330	2026-10-06
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) NCT06941272	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	64	2026-10-06
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) NCT06395103	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	71	2026-10-06
TeliMET NSCLC-01 NCT04928846	Phase 3	Recruiting	AbbVie	317	2026-10-05
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) NCT07144280	Phase 3	Recruiting	Pfizer	449	2026-09-28
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue NCT06989437	Phase 2/3	Recruiting	Pfizer	223	2026-09-25
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. NCT06629779	Phase 3	Recruiting	Pfizer	233	2026-09-25
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lu NCT06758401	Phase 3	Recruiting	Pfizer	389	2026-09-25
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL NCT05748171	Phase 2	Recruiting	Pfizer	65	2026-09-24
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking En NCT07028853	Phase 3	Recruiting	Pfizer	307	2026-09-24
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-sma NCT06452277	Phase 3	Recruiting	Bayer	279	2026-09-23
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. NCT05939414	Phase 3	Recruiting	Novartis Pharmaceuticals	144	2026-09-22
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal NCT06252649	Phase 3	Recruiting	Amgen	291	2026-09-03
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other NCT06152575	Phase 3	Recruiting	Pfizer	270	2026-08-24
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer NCT06467357	Phase 3	Recruiting	AstraZeneca	269	2026-08-19
MOUNTAINEER NCT03043313, NCT05253651	Phase 2	Recruiting	Seagen Inc.	422	2026-07-22
MOUNTAINEER-03 NCT05253651	Phase 3	Recruiting	Seagen, a wholly owned subsidiary of Pfizer	366	2026-07-22
RADAR NCT04685616	Phase 3	Recruiting	University College, London	72	2026-07-08
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC NCT05491525	Phase 2/3	Recruiting	Urovant Sciences GmbH	38	2026-06-15
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma NCT06588478	Phase 2	Recruiting	Loxo Oncology, Inc.	131	2026-05-19
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment NCT07062965	Phase 3	Recruiting	Pfizer	202	2026-05-06
Neoadjuvant Darovasertib in Primary Uveal Melanoma NCT07015190	Phase 3	Recruiting	IDEAYA Biosciences	94	2026-05-06
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) NCT04221035	Phase 3	Recruiting	Gustave Roussy, Cancer Campus, Grand Paris	142	2025-06-26
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis NCT05201404	Phase 3	Recruiting	Can-Fite BioPharma	32	2025-04-29
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors NCT03709680	Phase 2	Completed	Pfizer	84	2026-10-07
AMPLIFY NCT03836261	Phase 3	Active not recruiting	Acerta Pharma BV	169	2026-10-05
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) NCT03407144	Phase 2	Active not recruiting	Merck Sharp & Dohme LLC	93	2026-10-02
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer NCT06764485	Phase 3	Active not recruiting	Celgene	227	2026-09-30
XPORT-EC-042 / ENGOT-EN20 / GOG-3083 NCT05611931	Phase 3	Active not recruiting	Karyopharm Therapeutics Inc	191	2026-09-30

(showing the first 30)

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Slovakia, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Slovakia is open is on the registry page, under Contacts and Locations.

Institutions, companies and people

1 institution

Biomedical Research Center of the Slovak Academy of Sciences

1 person

People whose main affiliation in OnCo is an institution or company in Slovakia.

Miroslav Chovanec

Approvals

Slovakia is an EU member state, so an EU centralised authorisation covers it: 309 products in OnCo carry a sourced EU row that is approved or conditional. See the approvals by region matrix. National procedures and reimbursement are not recorded.

What OnCo does not yet hold

No registry figures. The figures above are IARC's estimates; OnCo has not read Slovakia's own cancer registry, its survival figures or its stage at diagnosis.
No payer detail: who pays for cancer care in Slovakia, what a patient pays, and which medicines are reimbursed.
No regulator detail: the national medicines agency's own procedures, beyond EU centralised authorisations.
No national cancer plan, guideline, screening schedule or treatment-centre list read from Slovakia's own sources.

Slovakia is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.

Sources and machine-readable data

IARC Global Cancer Observatory, GLOBOCAN 2024: Cancer Today.
ClinicalTrials.gov study records, courtesy of the US National Library of Medicine, as captured in each trial record.
OnCo records: each chip and card opens a record with its own sources.
This page as JSON: /api/v1/countries/sk.json; every country: /api/v1/countries.json.